高リン血症治療薬のアジア太平洋市場

◆英語タイトル:Asia Pacific Hyperphosphatemia Drug Market Forecast 2017-2025
◆商品コード:INKW709079
◆発行会社(調査会社):Inkwood Research
◆発行日:2017年6月24日
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

KEY FINDINGSThe Asia-Pacific hyperphosphatemia drugs market is worth $578 million in 2017. The market is estimated to grow at a CAGR of 17.52% during the forecast period of 2017-2025 and generate $ 2445 million by the end of 2025. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The growing prevalence of such chronic diseases, increasing elderly population, unmet medical attention, and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market in this region. The Asia-Pacific regions are expected to further propel the growth of the market in the coming years.

MARKET INSIGHTS
Increased cases of osteoporosis in the aging population are observed in the Asia-Pacific regions, which is mostly going undertreated and underdiagnosed. This lapse is majorly responsible for the demand of the hyperphosphatemia drugs market in the Asian countries. The Indian hyperphosphatemia drugs market is growing with highest CAGR of 18.74% during the forecast period. Growing elderly population in India is the key driving factor responsible for increasing the demand of the hyperphosphatemia drugs market in this region. The hyperphosphatemia drug market is segmented on the basis of the drug formulation. They include iron-based phosphate binders, calcium-based phosphate binders, magnesium-based phosphate binders, aluminum-based phosphate binders, and other phosphate binders. The Calcium-based phosphate binder’s formulation is expected to lead the hyperphosphatemia drugs market during the forecast years. The Aluminium-based phosphate binders generated a revenue of $203 million in 2016 and are widely being used for the treatment of hyperphosphatemia in dialysis patients. The magnesium-based phosphorus binders are another widely used phosphorus binders, that too, are remarkably being engaged in curing the hyperphosphatemia conditions in all the dialysis patients.
COMPETITIVE INSIGHTS
The major players in the hyperphosphatemia drug market are Johnson And Johnson, Cipla, Dsm, Biotech Pharmacal, Sun Pharm Inc, Zeria Pharmaceutical, Ultragenyx, Bruno Farmaceutici Spa, Fermenta Biotech Ltd, Fresenius Medical Care Pfizer Inc, Roche Diagnostics Corporation, Keryx Biopharmaceuticals , R.H. Moore Drug Co, Vifor Pharma, Sanofi, and Amag Pharmaceuticals

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. GROWING PREVALENCE OF CHRONIC DISEASES
4.1.2. UNMET MEDICAL NEEDS
4.1.3. HIGH PROPORTION OF ELDERLY PEOPLE
4.1.4. RISE IN PUBLIC AWARENESS
4.2. RESTRAINTS
4.2.1. LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION(FDA)
4.2.2. GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
4.3. OPPORTUNITIES
4.3.1. ASIA PACIFIC REGIONS ARE EXPECTED TO PROPEL THE MARKET GROWTH
4.4. CHALLENGES
4.4.1. NON-ADHERENCE TO TREATMENT REGIMENS
4.4.2. SIDE EFFECTS OF DRUGS
4.4.3. LIMITED AVAILABILITY OF DRUGS
4.4.4. USE OF ADVANCED DIALYSIS TECHNIQUES
5. MARKET SEGMENTATION
5.1. MARKET BY FORMULATION
5.1.1. CALCIUM-BASED PHOSPHATE BINDERS
5.1.2. ALUMINUM-BASED PHOSPHATE BINDERS
5.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS
5.1.4. IRON-BASED PHOSPHATE BINDERS
5.1.5. OTHER PHOSPHATE BINDERS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. BARGAINING POWER OF BUYERS
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. THREAT OF SUBSTITUTE PRODUCT
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. OPPORTUNITY MATRIX
6.3. KEY BUYING CRITERIA
6.3.1. APPLICATION
6.3.2. PRICING
6.3.3. EFFECTIVENESS
6.3.4. AVAILABILITY
6.4. STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
7. GEOGRAPHIC ANALYSIS
7.1. ASIA PACIFIC
7.1.1. INDIA
7.1.2. CHINA
7.1.3. JAPAN
7.1.4. AUSTRALIA
7.1.5. ROAPAC
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
8.2.1. CASE STUDIES: TOP COMPETITIVE MOVES
9. COMPANY PROFILE
9.1. AMAG PHARMACEUTICALS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC ANALYSIS
9.2. JOHNSON AND JOHNSON
9.2.1. COMPANY OVERVIEW
9.2.2. SCOT ANALYSIS
9.2.3. STRATEGIC ANALYSIS
9.3. CIPLA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC ANALYSIS
9.4. KERYX BIOPHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVES
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC ANALYSIS
9.5. DSM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. BIOTECH PHARMACAL
9.6.1. OVERVIEW
9.6.2. STRATEGIC INITIATIVES
9.6.3. PRODUCTS PORTFOLIO
9.6.4. SCOT ANALYSIS
9.7. SUN PHARM INC
9.7.1. OVERVIEW
9.7.2. STRATEGIC INITIATIVE
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC ANALYSIS
9.8. ZERIA PHARMACEUTICAL
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC ANALYSIS
9.9. ULTRAGENYX
9.9.1. OVERVIEW
9.9.2. SCOT ANALYSIS
9.9.3. STRATEGIC ANALYSIS
9.10. BRUNO FARMACEUTICI SPA
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. FERMENTA BIOTECH LTD
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC ANALYSIS
9.12. PFIZER INC.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.13. ROCHE DIAGNOSTICS CORPORATION
9.13.1. OVERVIEW
9.13.2. STRATEGIC INITIATIVES
9.13.3. SCOT ANALYSIS
9.13.4. PRODUCT PORTFOLIO
9.13.5. STRATEGIC ANALYSIS
9.14. R.H. MOORE DRUG CO.
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT
9.14.4. STRATEGIC ANALYSIS
9.15. VIFOR PHARMA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT
9.15.4. STRATEGIC ANALYSIS
9.16. SANOFI
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC ANALYSIS
9.17. SHIRE
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC ANALYSIS
9.18. FRESENIUS MEDICAL CARE
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC ANALYSIS

TABLE LIST
TABLE # 1 ASIA PACIFIC HYPERPHOSPHATEMIA DRUG MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
TABLE # 3 WORLDWIDE PREVALENCE OF DIABETES 2015 AND 2035 (MILLIONS)
TABLE # 4 WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)
TABLE # 5 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE # 6 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 7 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 8 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 9 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 10 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 11 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 12 ASIA-PACIFICHYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
TABLE # 13 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

FIGURE LIST
FIGURE # 1 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE # 2 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
FIGURE # 3 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 4 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 5 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 6 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 7 ASIA PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 8 PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET
FIGURE # 9 MARKET SHARE OF ANALYSIS OF KEY PLAYERS 2016 (%)
FIGURE # 10 AGE WISE DISTRIBUTION OF INDIAN POPULATION
FIGURE # 11 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 12 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 13 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 14 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)
FIGURE # 15 AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 16 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)



【レポートのキーワード】

高リン血症治療薬

★調査レポート[高リン血症治療薬のアジア太平洋市場] (コード:INKW709079)販売に関する免責事項を必ずご確認ください。
★調査レポート[高リン血症治療薬のアジア太平洋市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆